Pliant Therapeutics Presents Data From Phase 1 Trial Of PLN-101095 At AACR Annual Meeting 2026
Benzinga Newsdesk 7 months ago
News
Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of
Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026.
The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium.